Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Boston Scientific Corporation or Danaher Corporation because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Boston Scientific Corporation and Danaher Corporation compare based on key financial metrics to determine which better meets your investment needs.

About Boston Scientific Corporation and Danaher Corporation

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Latest Health Care Equipment & Supplies and Boston Scientific Corporation, Danaher Corporation Stock News

As of September 1, 2026, Boston Scientific Corporation had a $69.7 billion market capitalization, compared to the Health Care Equipment & Supplies median of $405.9 million. Boston Scientific Corporation’s stock is NA in 2026, NA in the previous five trading days and down 54.43% in the past year.

Currently, Boston Scientific Corporation’s price-earnings ratio is 19.5. Boston Scientific Corporation’s trailing 12-month revenue is $21.0 billion with a 17.5% net profit margin. Year-over-year quarterly sales growth most recently was 7.5%. Analysts expect adjusted earnings to reach $3.304 per share for the current fiscal year. Boston Scientific Corporation does not currently pay a dividend.

Currently, Danaher Corporation’s price-earnings ratio is 36.9. Danaher Corporation’s trailing 12-month revenue is $25.1 billion with a 15.9% net profit margin. Year-over-year quarterly sales growth most recently was 5.5%. Analysts expect adjusted earnings to reach $8.510 per share for the current fiscal year. Danaher Corporation currently has a 0.8% dividend yield.

How We Compare Boston Scientific Corporation and Danaher Corporation Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Boston Scientific Corporation and Danaher Corporation’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Boston Scientific Corporation and Danaher Corporation Growth Grades

Company	Ticker	Growth
Boston Scientific Corporation	BSX	A
Danaher Corporation	DHR	C

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Boston Scientific Corporation has a Growth Score of 89, which is Very Strong. Danaher Corporation has a Growth Score of 56, which is Average.

The Growth Grade Winner: Boston Scientific Corporation

As you can clearly see from the Growth Grade breakdown above, Boston Scientific Corporation has a more attractive growth grade than Danaher Corporation. For investors who focus solely on how a company is growing relative to other companies in the same industry, Boston Scientific Corporation could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Boston Scientific Corporation and Danaher Corporation’s Momentum Grades

Company	Ticker	Momentum
Boston Scientific Corporation	BSX	F
Danaher Corporation	DHR	C

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Boston Scientific Corporation has a Momentum Score of 15, which is Very Weak. Danaher Corporation has a Momentum Score of 54, which is Average.

The Momentum Stock Winner: No Clear Winner

Neither Boston Scientific Corporation or Danaher Corporation has a strong enough Momentum Grade to be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Boston Scientific Corporation or Danaher Corporation is the better investment when it comes to momentum.

Boston Scientific Corporation and Danaher Corporation’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Boston Scientific Corporation	BSX	C
Danaher Corporation	DHR	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Boston Scientific Corporation has a Earnings Estimate Score of 48, which is Neutral. Danaher Corporation has a Earnings Estimate Score of 67, which is Positive.

The Earnings Estimate Revisions Grade Winner: Danaher Corporation

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Danaher Corporation has a better Earnings Estimate Revisions Grade than Boston Scientific Corporation. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Danaher Corporation could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Boston Scientific Corporation and Danaher Corporation Grades

In addition to Growth, Estimate Revisions and Momentum, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Boston Scientific Corporation and Danaher Corporation pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Boston Scientific Corporation or Danaher Corporation Stock?

Overall, Boston Scientific Corporation stock has a Growth Score of 89, Momentum Score of 15 and Estimate Revisions Score of 48.

Danaher Corporation stock has a Growth Score of 56, Momentum Score of 54 and Estimate Revisions Score of 67.

Comparing Boston Scientific Corporation and Danaher Corporation’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.